Table 1.
Demographics and baseline characteristics
| Ponezumab (n = 24) | Placebo (n = 12) | |
|---|---|---|
| Gender, Male (%) | 16 (66.7) | 7 (58.3) |
| Age, Mean (SD) | 68.8 (6.8) | 65.0 (5.7) |
| Weight, Mean (SD) kg | 75.3 (14.5) | 73.5 (12.1) |
| BMI, Mean (SD) kg/m2 | 25.9 (3.0) | 25.2 (3.7) |
| Height, Mean (SD), cm | 169.6 (10.5) | 170.6 (11.9) |
| Lobar CMB (%) | ||
| 0–10 | 8 (33.3) | 5 (41.7) |
| 11–40 | 4 (16.7) | 3 (25.0) |
| 41–100 | 2 (8.3) | 1 (8.3) |
| 101–300 | 4 (16.7) | 2 (16.7) |
| >300 | 6 (25.0) | 1 (8.3) |
| Overall (>0) | 23 (95.8) | 12 (100.0) |
| Intracranial hemorrhage | 13 (54.2) | 6 (50.0) |
| Superficial siderosis | 14 (58.3) | 7 (58.3) |
| White matter hyperintensities | ||
| Absent | 1 (4.2) | 2 (16.7) |
| Mild | 8 (33.3) | 4 (33.3) |
| Moderate | 13 (54.2) | 5 (41.7) |
| Severe | 2 (8.3) | 1 (8.3) |
| Apolipoprotein E genotype: | ||
| E2/E3 | 2 (8.3) | 0 |
| E2/E4 | 4 (16.7) | 2 (16.7) |
| E3/E3 | 6 (25.0) | 7 (58.3) |
| E3/E4 | 5 (20.8) | 1 (8.3) |
| E4/E4 | 7 (29.2) | 2 (16.7) |
| MMSE, mean (SD) | 28.8 (1.24) | 28.8 (1.06) |
| MoCA, mean (SD) | 25.5 (3.41) | 25.9 (3.34) |
| Stable use of antiepileptic drug | 3 (12.5) | 0 |
| Stable use of antiinflammatory drug: | ||
| For treatment of CAAa | 0 | 0 |
| For treatment of other conditionb | 3 (12.5) | 1 (8.3) |
| Baseline BOLD fMRI parametersc, mean (SD) | ||
| Slope (percent/second) | 0.12 (0.08) | 0.15 (0.06) |
| Time to peak (seconds) | 11.92 (1.85) | 11.39 (2.12) |
| Amplitude (percent) | 1.36 (0.71) | 1.69 (0.59) |
| Time to return to baseline (seconds) | 12.17 (1.63) | 11.91 (1.95) |
Abbreviations: BOLD, blood oxygenation level dependent; CAA, cerebral amyloid angiopathy; CMB, cerebral microbleeds; fMRI, functional magnetic resonance imaging; MMSE, Mini Mental State Examination; MoCA, Montreal Cognitive Assessment; n, number of subjects; ROI, region of interest; SD, standard deviation.
a
Include aspirin and oral/intravenous steroids.
b
Include any nonsteroidal antiinflammatory drugs and topical/oral/intravenous steroids.
c
BOLD fMRI parameters were from ROI1.